MedTrace Logo

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

NCT03545035 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2022-05-12

No results posted yet for this study

Summary

The present study aims at obtaining more in-depth information on how patients with chronic lymphocytic leukemia treated with idelalisib and rituximab react to treatment.

Conditions

Interventions

DRUG

idelalisib and rituximab

patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab

Sponsors & Collaborators

  • ERIC Group

    collaborator UNKNOWN

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Antonio Cuneo · Ematologia; Azienda Ospedaliera di Ferrara

  • Gian Matteo Rigolin · Ematologia; Azienda Ospedaliera di Ferrara

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-06
Primary Completion
2020-10-28
Completion
2020-10-28

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03545035 on ClinicalTrials.gov